NeuroSense Therapeutics Ownership 2024 | Who Owns NeuroSense Therapeutics Now?
Institutional Ownership
10.85%
Insider Ownership
25.43%
Retail Ownership
63.72%
Institutional Holders
7.00
NeuroSense Therapeutics Institutional Shareholders
Institutional Shareholders by % of Total Shares
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 10.28% | 0.02% | 1,584,000 | 1,584,000 | 100.00% | 1,774,080 | Jun 30, 2024 |
| MEITAV INVESTMENT HOUSE LTD | 0.26% | 0.00% | 40,000 | -10,000 | -20.00% | 44,800 | Jun 30, 2024 |
| XTX TOPCO LTD | 0.21% | 0.00% | 32,650 | 32,650 | 100.00% | 36,568 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.08% | - | 11,963 | - | - | 13,398 | Jun 30, 2024 |
| MORGAN STANLEY | 0.01% | - | 1,500 | - | - | 1,680 | Jun 30, 2024 |
| CWM, LLC | 0.01% | - | 1,000 | - | - | 1,000 | Jun 30, 2024 |
| QUBE RESEARCH & TECHNOLOGIES LTD | 0.00% | - | 54 | - | - | 60 | Jun 30, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | - | - | - | -71,100 | -100.00% | - | Jun 30, 2024 |
| UBS GROUP AG | - | - | - | -11,928 | -100.00% | - | Jun 30, 2024 |
| WOODLINE PARTNERS LP | - | - | - | -19,581 | -100.00% | - | Jun 30, 2024 |
NeuroSense Therapeutics's largest institutional shareholder is ARMISTICE CAPITAL, LLC, holding 10.28% of the company's total share outstanding, currently valued at $1.77M. The top 10 institutional shareholders own together 10.85% of the company.
Institutional Shareholders by % of Total Assets
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 10.28% | 0.02% | 1,584,000 | 1,584,000 | 100.00% | 1,774,080 | Jun 30, 2024 |
| XTX TOPCO LTD | 0.21% | 0.00% | 32,650 | 32,650 | 100.00% | 36,568 | Jun 30, 2024 |
| MEITAV INVESTMENT HOUSE LTD | 0.26% | 0.00% | 40,000 | -10,000 | -20.00% | 44,800 | Jun 30, 2024 |
| CWM, LLC | 0.01% | - | 1,000 | - | - | 1,000 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.08% | - | 11,963 | - | - | 13,398 | Jun 30, 2024 |
| MORGAN STANLEY | 0.01% | - | 1,500 | - | - | 1,680 | Jun 30, 2024 |
| QUBE RESEARCH & TECHNOLOGIES LTD | 0.00% | - | 54 | - | - | 60 | Jun 30, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | - | - | - | -71,100 | -100.00% | - | Jun 30, 2024 |
| UBS GROUP AG | - | - | - | -11,928 | -100.00% | - | Jun 30, 2024 |
| WOODLINE PARTNERS LP | - | - | - | -19,581 | -100.00% | - | Jun 30, 2024 |
The largest NeuroSense Therapeutics shareholder by % of total assets is ARMISTICE CAPITAL, LLC. The company owns 1.58M shares of NeuroSense Therapeutics (NRSN), representing 0.02% of its total assets.
Institutional Buyers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 10.28% | 0.02% | 1,584,000 | 1,584,000 | 100.00% | 1,774,080 | Jun 30, 2024 |
| XTX TOPCO LTD | 0.21% | 0.00% | 32,650 | 32,650 | 100.00% | 36,568 | Jun 30, 2024 |
| QUBE RESEARCH & TECHNOLOGIES LTD | 0.00% | - | 54 | - | - | 60 | Jun 30, 2024 |
| MORGAN STANLEY | 0.01% | - | 1,500 | - | - | 1,680 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.08% | - | 11,963 | - | - | 13,398 | Jun 30, 2024 |
| CWM, LLC | 0.01% | - | 1,000 | - | - | 1,000 | Jun 30, 2024 |
| MEITAV INVESTMENT HOUSE LTD | 0.26% | 0.00% | 40,000 | -10,000 | -20.00% | 44,800 | Jun 30, 2024 |
| UBS GROUP AG | - | - | - | -11,928 | -100.00% | - | Jun 30, 2024 |
| WOODLINE PARTNERS LP | - | - | - | -19,581 | -100.00% | - | Jun 30, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | - | - | - | -71,100 | -100.00% | - | Jun 30, 2024 |
As of Jun 30 2024, NeuroSense Therapeutics's largest institutional buyer is ARMISTICE CAPITAL, LLC. The company purchased 1.58M stocks of NRSN, valued at $1.77M.
Institutional Sellers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | - | - | - | -71,100 | -100.00% | - | Jun 30, 2024 |
| WOODLINE PARTNERS LP | - | - | - | -19,581 | -100.00% | - | Jun 30, 2024 |
| UBS GROUP AG | - | - | - | -11,928 | -100.00% | - | Jun 30, 2024 |
| MEITAV INVESTMENT HOUSE LTD | 0.26% | 0.00% | 40,000 | -10,000 | -20.00% | 44,800 | Jun 30, 2024 |
| CWM, LLC | 0.01% | - | 1,000 | - | - | 1,000 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.08% | - | 11,963 | - | - | 13,398 | Jun 30, 2024 |
| MORGAN STANLEY | 0.01% | - | 1,500 | - | - | 1,680 | Jun 30, 2024 |
| QUBE RESEARCH & TECHNOLOGIES LTD | 0.00% | - | 54 | - | - | 60 | Jun 30, 2024 |
| XTX TOPCO LTD | 0.21% | 0.00% | 32,650 | 32,650 | 100.00% | 36,568 | Jun 30, 2024 |
| ARMISTICE CAPITAL, LLC | 10.28% | 0.02% | 1,584,000 | 1,584,000 | 100.00% | 1,774,080 | Jun 30, 2024 |
As of Jun 30 2024, NeuroSense Therapeutics's biggest institutional seller is RENAISSANCE TECHNOLOGIES LLC. The company sold -71.10K shares of NRSN, valued at -.
Institutional New positions
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 10.28% | 0.02% | 1,584,000 | 1,584,000 | 100.00% | 1,774,080 | Jun 30, 2024 |
| XTX TOPCO LTD | 0.21% | 0.00% | 32,650 | 32,650 | 100.00% | 36,568 | Jun 30, 2024 |
NeuroSense Therapeutics's largest new institutional shareholder by number of shares is ARMISTICE CAPITAL, LLC, purchased 1.58M shares, valued at $1.77M, as of undefined.
Institutional Sold Out
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | - | - | - | -71,100 | -100.00% | - | Jun 30, 2024 |
| WOODLINE PARTNERS LP | - | - | - | -19,581 | -100.00% | - | Jun 30, 2024 |
| UBS GROUP AG | - | - | - | -11,928 | -100.00% | - | Jun 30, 2024 |
NeuroSense Therapeutics's largest sold out institutional shareholder by shares sold is RENAISSANCE TECHNOLOGIES LLC, sold -71.10K shares, valued at -, as of undefined.
NeuroSense Therapeutics Institutional Ownership Trends
Institutional Holdings Trend
| Date | Holdings | Change % |
|---|---|---|
| 30 Jun, 24 | 7 | -12.50% |
| 31 Mar, 24 | 8 | - |
| 31 Dec, 23 | 8 | 60.00% |
| 30 Sep, 23 | 5 | -16.67% |
| 30 Jun, 23 | 6 | 20.00% |
| 31 Mar, 23 | 5 | - |
| 31 Dec, 22 | 5 | 25.00% |
| 30 Sep, 22 | 4 | -42.86% |
| 30 Jun, 22 | 7 | - |
| 31 Mar, 22 | 7 | 40.00% |
| 31 Dec, 21 | 5 | - |
As of 30 Jun 24, 7 institutions are holding NeuroSense Therapeutics's shares, representing a decrease of -12.50% compared to the previous quarter.
Shares Outstanding Trend
| Date | Shares Outstanding | Change % |
|---|---|---|
| 30 Jun, 24 | 1,671,167 | 899.94% |
| 31 Mar, 24 | 167,126 | 18.03% |
| 31 Dec, 23 | 141,595 | -81.83% |
| 30 Sep, 23 | 779,367 | -47.14% |
| 30 Jun, 23 | 1,474,496 | 1090.92% |
| 31 Mar, 23 | 123,812 | 256.87% |
| 31 Dec, 22 | 34,694 | -52.90% |
| 30 Sep, 22 | 73,659 | -66.10% |
| 30 Jun, 22 | 217,265 | 28.67% |
| 31 Mar, 22 | 168,852 | 8.96% |
| 31 Dec, 21 | 154,961 | - |
NeuroSense Therapeutics (NRSN) has 1.67M shares outstanding as of 30 Jun 24, up 899.94% compared to the previous quarter.
Institutional Ownership Trend
| Date | Ownership % | Change % |
|---|---|---|
| 30 Jun, 24 | 10.85% | 918.60% |
| 31 Mar, 24 | 1.09% | 84.21% |
| 31 Dec, 23 | 1.14% | 4.47% |
| 30 Sep, 23 | 5.04% | 3.22% |
| 30 Jun, 23 | 12.51% | 1133.56% |
| 31 Mar, 23 | 1.05% | 1155.11% |
| 31 Dec, 22 | 0.30% | 73.56% |
| 30 Sep, 22 | 0.64% | 16.40% |
| 30 Jun, 22 | 1.98% | 83.78% |
| 31 Mar, 22 | 1.54% | 24.93% |
| 31 Dec, 21 | 2.48% | - |
As of 30 Jun 24, NeuroSense Therapeutics is held by 10.85% institutional shareholders, representing a 918.60% growth compared to 31 Mar 24.
Institutional Increased Positions Trend
| Date | Increased Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 2 | -33.33% |
| 31 Mar, 24 | 3 | -40.00% |
| 31 Dec, 23 | 5 | 150.00% |
| 30 Sep, 23 | 2 | -33.33% |
| 30 Jun, 23 | 3 | - |
| 31 Mar, 23 | 3 | 50.00% |
| 31 Dec, 22 | 2 | - |
| 30 Sep, 22 | 2 | -71.43% |
| 30 Jun, 22 | 7 | 40.00% |
| 31 Mar, 22 | 5 | - |
| 31 Dec, 21 | 5 | - |
2 institutional shareholders have increased their position in NRSN stock as of 30 Jun 24 compared to 3 in the previous quarter (a -33.33% decrease).
Institutional Reduced Positions Trend
| Date | Reduced Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 1 | - |
| 31 Mar, 24 | 1 | - |
| 31 Dec, 23 | 1 | - |
| 30 Sep, 23 | 1 | - |
| 30 Jun, 23 | - | - |
| 31 Mar, 23 | - | -100.00% |
| 31 Dec, 22 | 2 | - |
| 30 Sep, 22 | 2 | - |
| 30 Jun, 22 | - | -100.00% |
| 31 Mar, 22 | 2 | - |
| 31 Dec, 21 | - | - |
1 institutional shareholders have reduced their position in NRSN stock as of 30 Jun 24 compared to 1 in the previous quarter (a 0.00% increase).
All Institutional Ownership Trend Data
| Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| 30 Jun, 24 | 7 | -12.50% | 1,671,167 | 899.94% | 10.85% | 918.60% | 2 | -33.33% | 1 | - |
| 31 Mar, 24 | 8 | - | 167,126 | 18.03% | 1.09% | 84.21% | 3 | -40.00% | 1 | - |
| 31 Dec, 23 | 8 | 60.00% | 141,595 | -81.83% | 1.14% | 4.47% | 5 | 150.00% | 1 | - |
| 30 Sep, 23 | 5 | -16.67% | 779,367 | -47.14% | 5.04% | 3.22% | 2 | -33.33% | 1 | - |
| 30 Jun, 23 | 6 | 20.00% | 1,474,496 | 1090.92% | 12.51% | 1133.56% | 3 | - | - | - |
| 31 Mar, 23 | 5 | - | 123,812 | 256.87% | 1.05% | 1155.11% | 3 | 50.00% | - | -100.00% |
| 31 Dec, 22 | 5 | 25.00% | 34,694 | -52.90% | 0.30% | 73.56% | 2 | - | 2 | - |
| 30 Sep, 22 | 4 | -42.86% | 73,659 | -66.10% | 0.64% | 16.40% | 2 | -71.43% | 2 | - |
| 30 Jun, 22 | 7 | - | 217,265 | 28.67% | 1.98% | 83.78% | 7 | 40.00% | - | -100.00% |
| 31 Mar, 22 | 7 | 40.00% | 168,852 | 8.96% | 1.54% | 24.93% | 5 | - | 2 | - |
| 31 Dec, 21 | 5 | - | 154,961 | - | 2.48% | - | 5 | - | - | - |
NeuroSense Therapeutics Peer Ownership
| Ticker | Company |
|---|---|
| BDRX | Biodexa Pharmaceuticals Plc |
| NTRB | Nutriband Inc. |
| BWV | Onconetix, Inc. |
| KPRX | Kiora Pharmaceuticals, Inc. |
| PXMD | PaxMedica, Inc. Common Stock |
| LGVN | Longeveron Inc. |
| REVB | Revelation Biosciences, Inc. |
| QNRX | Quoin Pharmaceuticals, Ltd. |
| HILS | Tharimmune, Inc. |
| VRAX | Virax Biolabs Group Limited |
| ALLR | Allarity Therapeutics, Inc. |
| RNXT | RenovoRx, Inc. |
| NRBO | NeuroBo Pharmaceuticals, Inc. |
NRSN Ownership FAQ
Who Owns NeuroSense Therapeutics?
NeuroSense Therapeutics is owned by institutional shareholders (10.85%), insiders (25.43%), and public (63.72%). The largest institutional shareholder of NeuroSense Therapeutics is ARMISTICE CAPITAL, LLC (10.28% of total shares) and the top mutual fund owner is (0% of total shares).
Who are the major institutional shareholders of NeuroSense Therapeutics?
NeuroSense Therapeutics's major institutional shareholders are ARMISTICE CAPITAL, LLC, MEITAV INVESTMENT HOUSE LTD, XTX TOPCO LTD, GEODE CAPITAL MANAGEMENT, LLC, and MORGAN STANLEY. The top five shareholders own together 10.84% of the company's share outstanding.
How many NeuroSense Therapeutics shareholders are there?
As of Jun 2024, there are 7 institutional shareholders of NeuroSense Therapeutics.
What percentage of NeuroSense Therapeutics is owned by ARMISTICE CAPITAL, LLC?
ARMISTICE CAPITAL, LLC owns 1.58M shares of NeuroSense Therapeutics, representing 10.28% of the company's total shares outstanding, valued at $1.77M (as of Jun 2024).
What percentage of NeuroSense Therapeutics is owned by MEITAV INVESTMENT HOUSE LTD?
As of Jun 2024, MEITAV INVESTMENT HOUSE LTD holds 40K shares of NeuroSense Therapeutics (NRSN), compromising 0.26% of the company, valued at $44.8K.
What percentage of NeuroSense Therapeutics is owned by XTX TOPCO LTD?
XTX TOPCO LTD is the third largest holder of NeuroSense Therapeutics. The company owns 32.65K of the company's shares outstanding (worth $36.57K).